These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 22998756)

  • 21. Azacitidine adverse effects in patients with myelodysplastic syndromes.
    San Miguel Amigo L; Franco Osorio R; Mercadal Vilchez S; Martínez-Francés A
    Adv Ther; 2011 Jun; 28 Suppl 4():6-11. PubMed ID: 21688207
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Azacitidine-associated pleuropericardial effusion in myelodysplastic syndrome: A case report.
    Goo K; Uy R; Roswarski J
    J Oncol Pharm Pract; 2019 Jul; 25(5):1248-1252. PubMed ID: 29933727
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Azacitidine in a patient with myelodysplastic syndrome: Impact of switching from a 5-day to the approved 7-day dosing schedule.
    Voso MT; Fianchi L; Criscuolo M; Greco M; D'Alo F; Hohaus S; Pagano L; Leone G
    Leuk Res; 2012 Jan; 36(1):e15-7. PubMed ID: 21907408
    [No Abstract]   [Full Text] [Related]  

  • 24. 5'-Azacitidine for therapy-related myelodysplastic syndromes after non-Hodgkin lymphoma treatment.
    Breccia M; Salaroli A; Loglisci G; Martelli M; D'Elia GM; Nanni M; Mauro FR; Alimena G
    Leuk Res; 2011 Oct; 35(10):1409-11. PubMed ID: 21680017
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [5-day decitabine for treatment of myelodysplastic syndromes with complex karyotype abnormalities and acute myeloid leukemia].
    Gao S; Hu XH; Qiu HY; Xu Y; Jin ZM; He GS; Tang XW; Han Y; Chen SN; Sun AN; Wu DP
    Zhonghua Xue Ye Xue Za Zhi; 2013 Jun; 34(6):542-3. PubMed ID: 23827117
    [No Abstract]   [Full Text] [Related]  

  • 26. Azacitidine-eligibility in higher-risk myelodysplastic syndromes and chronic myelomonocytic leukaemia: a registry-based study.
    Durairaj S; Keenan N; Hyslop A; Groves MJ; Bowen DT; Tauro S
    Br J Haematol; 2013 Apr; 161(2):280-2. PubMed ID: 23294041
    [No Abstract]   [Full Text] [Related]  

  • 27. Acute myeloblastic leukemia.
    Molina CA; Rodríguez MJ; de Marcos NS; Font P
    Adv Ther; 2011 Mar; 28 Suppl 3():10-6. PubMed ID: 21431629
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effectiveness and safety of different azacitidine dosage regimens in patients with myelodysplastic syndromes or acute myeloid leukemia.
    García-Delgado R; de Miguel D; Bailén A; González JR; Bargay J; Falantes JF; Andreu R; Ramos F; Tormo M; Brunet S; Figueredo A; Casaño J; Medina A; Badiella L; Jurado AF; Sanz G
    Leuk Res; 2014 Jul; 38(7):744-50. PubMed ID: 24795069
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Approval summary: azacitidine for treatment of myelodysplastic syndrome subtypes.
    Kaminskas E; Farrell A; Abraham S; Baird A; Hsieh LS; Lee SL; Leighton JK; Patel H; Rahman A; Sridhara R; Wang YC; Pazdur R;
    Clin Cancer Res; 2005 May; 11(10):3604-8. PubMed ID: 15897554
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cytogenetic response is not a prerequisite for clinical response in patients with myelodysplastic syndromes treated with azacitidine.
    Gangatharan SA; Carney DA; Campbell LJ; Prince HM; Kenealy MK; Seymour JF
    Eur J Haematol; 2011 Aug; 87(2):186-8. PubMed ID: 21623918
    [No Abstract]   [Full Text] [Related]  

  • 31. [The value of laminin-322 staining in distinguishing between keratoacanthoma, keratoacanthoma with areas of squamous cell carcinoma, and crateriform squamous cell carcinoma].
    Corbalán-Vélez R; Martínez-Barba E; López-Poveda MJ; Vidal-Abarca Gutiérrez I; Ruíz-Maciá JA; Oviedo-Ramirez I; Martínez-Menchón T
    Actas Dermosifiliogr; 2012 May; 103(4):308-16. PubMed ID: 22176864
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Use of hypomethylating agents in myelodysplastic syndromes.
    Atallah E; Garcia-Manero G
    Clin Adv Hematol Oncol; 2007 Jul; 5(7):544-52. PubMed ID: 17679928
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intravenous azacitidine for MDS.
    Gore SD
    Clin Adv Hematol Oncol; 2007 Mar; 5(3):234. PubMed ID: 17519884
    [No Abstract]   [Full Text] [Related]  

  • 34. [Topical therapy of precancerous lesions and skin carcinomas using a 5-fluorouracil ointment].
    Uthida-Tanaka AM; Nakamura S; de Britto-Costa R; de Tavares Mello E
    Hospital (Rio J); 1969 Dec; 76(6):2207-20. PubMed ID: 5309543
    [No Abstract]   [Full Text] [Related]  

  • 35. Efficacy of hypomethylating agents in therapy-related myelodysplastic syndromes.
    Klimek VM; Dolezal EK; Tees MT; Devlin SM; Stein K; Romero A; Nimer SD
    Leuk Res; 2012 Sep; 36(9):1093-7. PubMed ID: 22608310
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Optimizing therapy with methylation inhibitors in myelodysplastic syndromes: dose, duration, and patient selection.
    Issa JP
    Nat Clin Pract Oncol; 2005 Dec; 2 Suppl 1():S24-9. PubMed ID: 16341237
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Retinoids in the treatment of epithelial skin tumors].
    Berretti B; Grupper C
    Ther Umsch; 1986 Sep; 43(9):703-6. PubMed ID: 3535155
    [No Abstract]   [Full Text] [Related]  

  • 38. Azacitidine-associated hyperthermia and interstitial pneumonitis in a patient with myelodysplastic syndrome.
    Hueser CN; Patel AJ
    Pharmacotherapy; 2007 Dec; 27(12):1759-62. PubMed ID: 18041893
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Practical recommendations for hypomethylating agent therapy of patients with myelodysplastic syndromes.
    Steensma DP; Stone RM
    Hematol Oncol Clin North Am; 2010 Apr; 24(2):389-406. PubMed ID: 20359633
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical results with the DNA hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in patients with myelodysplastic syndromes: an update.
    Joeckel TE; Lübbert M
    Semin Hematol; 2012 Oct; 49(4):330-41. PubMed ID: 23079063
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.